BillionToOne Earnings Call Signals Profitable Hyper-Growth

BillionToOne, Inc. Class A ((BLLN)) has held its Q1 earnings call. Read on for the main highlights of the call.

BillionToOne’s latest earnings call painted a picture of a fast-growing diagnostics company hitting an inflection point, with strong revenue and volume growth feeding into rising margins and first-time GAAP profitability. Management acknowledged some risks around oncology margins, reimbursement timing, and quarterly volatility, but these were framed as manageable growing pains against a backdrop of robust cash generation and upgraded guidance.

Revenue Growth and Profitability

BillionToOne reported Q1 2026 revenue of $108.4 million, up 84% year over year, marking a sharp acceleration in scale. Operating income reached $17.8 million, translating into a 16% GAAP operating margin, while adjusted EBITDA margin stood at 24%, and net income swung to $18.0 million, or $0.34 per diluted share, from a loss a year ago.

Test Volume and ASP Expansion

The company processed about 188,000 tests in Q1, a 44% increase from the prior year as demand broadened across its portfolio. Average selling price climbed 28% year over year to $571 per test and rose $10 sequentially, helping push gross margin to 73% while overall COGS per test came in at $153, down 5% sequentially.

Prenatal Business Strength

Prenatal testing remained the cornerstone of the business, delivering $97.7 million in Q1 revenue, up 72% year over year and still the highest-margin segment. Prenatal volumes rose 10% sequentially, solidifying this franchise as the main engine behind the company’s expanding gross margins and overall profitability.

Rapid Oncology Ramp

Oncology revenue surged nearly fivefold to $10.7 million in Q1, implying an annualized run rate of roughly $43 million and underscoring a strong ramp in a newer segment. Volumes increased 25% quarter over quarter, and about 60% of NorthStar Select orders opted into CH, signaling robust clinical adoption despite the product still being in early scale-up.

Stronger Market Access and Payer Contracts

Market access improved meaningfully as BillionToOne secured an in-network contract with Anthem, pushing total contracted lives to about 300 million in the U.S., or over 90% of patients. UnitedHealthcare went in-network at the start of April, and management expects these marquee contracts to support further ASP expansion over time.

Product Innovation and Pipeline Progress

The company launched Unity Confirm, described as the first noninvasive fetal cell-based confirmation assay, with initial data showing 100% concordance to invasive diagnostics in early results. On the oncology side, new PGx and CH offerings were introduced, a tumor-naive MRD test is tracking toward a year-end launch, and the company has responded to MolDX feedback to advance coverage for its Response assay.

Raised 2026 Guidance

Riding the momentum from Q1, management lifted 2026 revenue guidance to a range of $445 million to $465 million, adding $20 million to both ends of the prior outlook. The revised guide implies 48% to 52% growth versus 2025 and is driven mainly by expected ASP gains rather than higher volumes, with profitability targeted near current levels despite ongoing investment.

Strong Balance Sheet and Cash Generation

BillionToOne closed the quarter with approximately $537 million in cash and equivalents, providing ample firepower to fund expansion and R&D. Cash flow from operations minus capital expenditures was $11.0 million in Q1, and management emphasized a dual focus on remaining profitable while still investing aggressively to capture growth opportunities.

Oncology Margin Pressure and COGS Risk

Despite oncology’s rapid growth, this segment currently carries lower margins due to subscale volumes and the absence of Medicare coverage for the Response assay. Executives cautioned that as oncology becomes a larger share of total volume, overall COGS per test could rise, creating some pressure on consolidated margins until reimbursement improves.

Dependence on Future Reimbursement Catalysts

Future financial upside in oncology hinges heavily on reimbursement wins, most notably Medicare coverage for NorthStar Response, which management is targeting by year-end. Any delay or unfavorable outcome would weigh on oncology ASPs and profitability, underlining how regulatory and payer decisions remain a key swing factor for the growth narrative.

Unity Confirm’s Limited Near-Term Revenue Impact

While Unity Confirm is positioned as a technological differentiator and clinical upgrade in prenatal care, its immediate financial contribution is expected to be modest, with only about 0.5% to 1% of patients estimated to be eligible. Management instead highlighted its strategic value in reinforcing the brand, supporting physician adoption, and potentially driving downstream volume across the broader testing portfolio.

Clinical Study Timelines and Data Uncertainty

The company is running a large prospective clinical study to further validate Unity Confirm against invasive diagnostics, but management indicated this effort may take one to three years to complete. Similarly, MRD adoption and broader clinical validation will unfold over multiple years, introducing inherent uncertainty in the pace at which these newer oncology products can scale.

Revenue Recognition Volatility and AR Spike

Q1 results included $9.2 million of true-up revenue, which management warned can create quarter-to-quarter swings in reported sales and margins. Accounts receivable also spiked, largely due to recently signed payer contracts, which adds short-term timing risk to cash collection even as the company expects these balances to normalize over time.

Operating Expense Growth

Operating expenses climbed to $61.2 million in Q1, up 52% year over year, with R&D at $14.7 million and SG&A at $46.6 million as the company scales its commercial footprint and pipeline. While Opex shrank as a percentage of revenue, management acknowledged that sustaining current margin levels will require continued strong top-line growth to absorb these elevated investment levels.

Seasonality and Sequential Volatility

Executives reminded investors that the business exhibits seasonality, with Q4 typically slower and Q2 and Q3 expected to show more sequential growth. They also flagged that ASPs, gross margins, and test volumes may fluctuate quarter to quarter due to true-ups, payer timing, and product mix shifts, meaning investors should focus more on annual trends than single-quarter noise.

Forward-Looking Guidance and Outlook

Looking ahead, management reiterated expectations for full-year gross margins of at least 70% and plans to sustain profitability even as they invest in oncology and new products. The updated 2026 guide is anchored in Q1’s strong metrics, including an annualized revenue run rate of roughly $434 million, and assumes normalization of accounts receivable, sequential growth through Q3, and a more muted Q4.

BillionToOne’s earnings call sketched a story of a diagnostics company moving decisively into profitable high-growth territory, powered by a dominant prenatal franchise and a fast-rising oncology business. While reimbursement, margin mix, and quarterly noise remain watchpoints, upgraded guidance, strong cash reserves, and a robust innovation pipeline give investors plenty of reasons to stay engaged with the stock’s long-term trajectory.